Search research articles
Contact Us
Filters
Showing results (151-160 of 177) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
Maria Gebre-Medhin, Eva Brun, Per Engström, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2025
Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer-Mature Results of the ARTSCAN III Trial
Maria Gebre-Medhin, Gabriel Adrian, Per Engström, et al.
Journal of Neurochemistry
|
August 5, 2020
Benzimidazole-based fluorophores for the detection of amyloid fibrils with higher sensitivity than Thioflavin-T
Narayanaperumal Pravin, Rakesh Kumar, Shalini Tripathi, et al.
Progress in Neurobiology
|
February 17, 2024
Signal peptide peptidase-like 2b modulates the amyloidogenic pathway and exhibits an Aβ-dependent expression in Alzheimer's disease
Riccardo Maccioni, Caterina Travisan, Jack Badman, et al.
Brain, Behavior, and Immunity
|
April 12, 2024
Dynamic microglia alterations associate with hippocampal network impairments: A turning point in amyloid pathology progression
Giusy Pizzirusso, Efthalia Preka, Julen Goikolea, et al.
Frontiers in Neuroscience
|
April 18, 2022
Recent Advances in the Modeling of Alzheimer's Disease
Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, et al.
Journal of Alzheimer'S Disease : JAD
|
November 19, 2025
Somatostatin receptor subtypes 1 and 4 regulate neprilysin, the major amyloid-β degrading enzyme in brain
Per Nilsson, Karin Sörgjerd, Naomasa Kakiya, et al.
The Lancet. Oncology
|
February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Per Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology
|
January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Lancet (London, England)
|
June 23, 2019
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 177) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
Maria Gebre-Medhin, Eva Brun, Per Engström, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2025
Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer-Mature Results of the ARTSCAN III Trial
Maria Gebre-Medhin, Gabriel Adrian, Per Engström, et al.
Journal of Neurochemistry
|
August 5, 2020
Benzimidazole-based fluorophores for the detection of amyloid fibrils with higher sensitivity than Thioflavin-T
Narayanaperumal Pravin, Rakesh Kumar, Shalini Tripathi, et al.
Progress in Neurobiology
|
February 17, 2024
Signal peptide peptidase-like 2b modulates the amyloidogenic pathway and exhibits an Aβ-dependent expression in Alzheimer's disease
Riccardo Maccioni, Caterina Travisan, Jack Badman, et al.
Brain, Behavior, and Immunity
|
April 12, 2024
Dynamic microglia alterations associate with hippocampal network impairments: A turning point in amyloid pathology progression
Giusy Pizzirusso, Efthalia Preka, Julen Goikolea, et al.
Frontiers in Neuroscience
|
April 18, 2022
Recent Advances in the Modeling of Alzheimer's Disease
Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, et al.
Journal of Alzheimer'S Disease : JAD
|
November 19, 2025
Somatostatin receptor subtypes 1 and 4 regulate neprilysin, the major amyloid-β degrading enzyme in brain
Per Nilsson, Karin Sörgjerd, Naomasa Kakiya, et al.
The Lancet. Oncology
|
February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Per Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology
|
January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Lancet (London, England)
|
June 23, 2019
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
Page
of 18